Search research articles
Contact Us
Filters
Showing results (191-200 of 232) with videos related to
Page
of 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
Shivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.
JCO Precision Oncology
|
July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Scott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2007
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07
J Philip Kuebler, H Samuel Wieand, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology
|
December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri, X V Wang, V Makker, et al.
JCO Precision Oncology
|
January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H
April K S Salama, Victoria Wang, Erin R Macrae, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]
K L Jhaveri, X V Wang, V Makker, et al.
Page
of 24
Search research articles
Search
Showing results (191-200 of 232) with videos related to
Sort By:
Page
of 24
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
Shivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.
JCO Precision Oncology
|
July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Scott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2007
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07
J Philip Kuebler, H Samuel Wieand, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology
|
December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri, X V Wang, V Makker, et al.
JCO Precision Oncology
|
January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H
April K S Salama, Victoria Wang, Erin R Macrae, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]
K L Jhaveri, X V Wang, V Makker, et al.
Page
of 24